In vitro experiments have confirmed that anti-LAG3 antibodies can downregulate Tregs, increase their cytotoxic activity against CD8+ T cells, reduce IFN-γ secretion, and modulate the immune tolerance of AML cells. This evidence concerns the gene LAG3 and acute myeloid leukemia.